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Chronic renal transplant dysfunction is characterized by loss of renal function and tissue
remodeling, including chronic inflammation and lymph vessel formation. Proteoglycans are
known for their chemokine presenting capacity. We hypothesize that interruption of the lym-
phatic chemokine–proteoglycan interaction interferes with the lymphatic outflow of leuko-
cytes from the renal graft and might decrease the anti-graft allo-immune response.
Methods
In a rat renal chronic transplant dysfunction model (female Dark-Agouti to male Wistar
Furth), chemokines were profiled by qRT-PCR in microdissected tubulo-interstitial tissue.
Disruption of lymphatic chemokine–proteoglycan interaction was studied by (non-anticoagu-
lant) heparin-derived polysaccharides in vitro and in renal allografts. The renal allograft func-
tion was assessed by rise in plasma creatinine and urea.
Results
Within newly-formed lymph vessels of transplanted kidneys, numerous CD45+ leukocytes
were found, mainly MHCII+, ED-1-, IDO-, HIS14-, CD103- antigen presenting cells, most
likely representing a subset of dendritic cells. Treatment of transplanted rats with regular
heparin and two different (non-)anticoagulant heparin derivatives revealed worsening of kid-
ney function only in the glycol-split heparin treated group despite a two-fold reduction of
tubulo-interstitial leukocytes (p<0.02). Quantitative digital image analysis however revealed
increased numbers of intra-lymphatic antigen-presenting cells only in the glycol-split heparin
group (p<0.01). The number of intra-lymphatic leukocytes significantly correlates with
plasma creatinine and urea, and inversely with creatinine clearance.
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Conclusions
Treatment of transplanted rats with glycol-split heparin significantly increases the number of
intra-lymphatic antigen presenting cells, by increased renal diffusion of lymphatic chemo-
kines, thereby increasing the activation and recruitment of antigen presenting cells towards
the lymph vessel. This effect is unwanted in the transplantation setting, but might be advan-
tageous in e.g., dendritic cell vaccination.
Introduction
Chronic transplant dysfunction (CTD) is characterized by decline in kidney allograft function
over time and is related to progressive tissue remodeling in the transplanted kidney. Histologi-
cally, CTD is characterized by chronic lesions such as interstitial fibrosis and tubular atrophy,
transplant vasculopathy, focal segmental glomerulosclerosis and lymphangiogenesis [1–3].
Lymphangiogenesis is the growth of new lymph vessel via sprouting from existing lymph ves-
sels or by trans-differentiation of monocytes/macrophages into lymphatic endothelial cells,
processes which are often initiated by tissue inflammation [4]. A common hypothesis nowa-
days is that inflammation and lymphangiogenesis have mutual interactions. In the kidney,
inflammation promotes lymph angiogenesis by stimulating the production of lymphangio-
genic factors like vascular endothelial growth factor C (VEGF-C) by activated tubular epithelial
cells and macrophages [5,6], while lymph vessels can produce pro-inflammatory cytokines and
form the major exit route for leukocytes. MHC class II expressing antigen presenting cells
(APCs), mainly dendritic cells (DCs), are believed to be the leukocyte subtype exiting the inter-
stitium via lymph vessel in CTD and promote allorecognition and alloreactivity.
In transplantation, the exact role of lymphangiogenesis is not yet clear. Although a benefi-
cial hyaluronan draining effect of newly formed lymph vessels in lung transplants has recently
been discovered [7]. We and others showed that lymphangiogenesis is associated with poor
transplant prognosis [8,9], which might be related to an increased migration of DCs to lymph
nodes in transplanted organs suffering from lymphangiogenesis. Increased DC migration in
turn leads to increased antigen presentation in lymph nodes resulting in a stronger T and B
lymphocyte-mediated allo-immune response [6]. Efforts have been undertaken to block
lymph vessel formation in experimental transplantation models and has been shown to
increase graft survival [10]. However in the kidney, lymph vessel blockade might lead to renal
edema, which has already been shown in mTOR inhibitors like rapamycin and is thought to be
due to the inhibition of lymphangiogenesis [11]. Therefore, instead of focusing on the inhibi-
tion of lymphangiogenesis, reduction of renal interstitial leukocyte in- and efflux might be a
way to improve renal function and graft survival.
Most research on the mechanism and function of APCs has been done in DCs, which are
believed to be the most important APC. In DCs, pathogenic or non-self-antigen uptake causes
maturation and subsequent C-C chemokine receptor 7 (CCR7) expression on the cell surface.
Chemokine (C-C motif) ligand (CCL) 19 and CCL21 are ligands for CCR7 and both have been
shown to stimulate DC migration [12,13]. CCL21 is produced by lymphatic endothelial cells
and stored intracellularly. Upon release CCL21 and CCL19 bind to heparan sulfate proteogly-
cans (HSPGs) present in the basement membrane of lymph vessels and form a short chemo-
tactic gradient around the lymph vessel [14,15]. The sulfation pattern of heparan sulfate (HS)
can influence its capability to bind CCL19 and CCL21 as shown by Yin and colleagues [16].
Besides CCL21 and 19, the lymph endothelial cells produce other chemokines like CX3CL1
and CXCL12 which are also believed to attract DCs via a chemotactic gradient. CXCL12
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probably via HS binding, but since CX3CL1 is a non-HS binding chemokine it is believed to
form a fluid phase gradient [17,18]. It is currently believed that the CX3CL1 and CXCL12 che-
motactic gradient causes DC migration towards the lymph vessel, where high concentrations
of CCL21 cause integrin activation and subsequent ICAM-1-mediated transmigration through
lymphatic endothelium [18]. CC-chemokines like CCL2 and CCL5, involved in HS mediated
DC influx from the blood, might also play a role in DC migration towards the lymphatic sys-
tem since it has been shown that these chemokines are upregulated in lymphatic endothelial
cells in inflammatory conditions [19].
It has been recognized already for some time that proteoglycans play a pivotal role in the
inflammatory process. Therefore strategies have been developed to use the proteoglycan che-
mokine interaction as a target for therapy. In kidney transplantation it has been shown that
treatment with multiple low molecular weight heparins reduce signs of progressive renal fail-
ure in experimental renal transplantation [20,21]. In these studies the authors showed that low
molecular weight (LMW) heparin reduces renal monocyte, T-cell and major histocompatibil-
ity complex II positive (MHCII+) infiltration. However none of these studies reported on the
effect of heparinoids on the migration of leukocytes towards the lymph vessels. Furthermore,
these studies were done with LWM heparin with anti-coagulant properties besides anti-
inflammatory properties. Anti-coagulant heparin has been shown to result in an increased risk
of hemorrhagic complications in patients early after transplantation [22]. This shows that the
anti-coagulant function of heparin is a major burden for the application of heparin in anti-
inflammatory treatment. However in experimental renal ischemia-reperfusion injury, it has
been demonstrated that treatment with a synthetic and non-anticoagulant heparin pentasac-
charide reduced inflammation and neutrophil accumulation [23,24]. This shows that non
anti-coagulant heparins might still exert anti-inflammatory effects despite losing their anti-
coagulant function. Therefore in this study we used, besides unfractionated heparin, two clini-
cally more favorable non anti-coagulant heparin derivatives, to evaluate the potency of these
heparins to interrupt the proteoglycan—chemokine interaction.
In this study we hypothesized that newly-formed lymph vessels in renal grafts are actively
involved in leukocyte migration from the graft towards the draining lymph node in order
to build an alloresponse. Secondly we hypothesized that interruption of chemokine–proteogly-
can interaction by non-anticoagulant heparin derivatives might interfere with the lymphatic
outflow of leukocytes from the renal graft and might decrease the anti-graft allo-immune
response.
Methods
Rat kidney transplantation model (Experiment 1)
Kidney allo-transplantation was performed from female Dark-Agouti (DA) donors to male
DA or Wistar Furth (WF) recipients according to standard procedures as described previously
[25]. The following experimental groups were included: control DA kidneys (N = 5), DA-to-
DA isografts (N = 5), and DA-to-WF allografts (N = 5). Isograft recipients were sacrificed at
day 81 (range 70–84) and allograft recipients at day 65 (range 54–84 days) after transplanta-
tion. The local animal ethics committee of the University of Groningen approved all the proce-
dures used in the study and the Principles of Laboratory Animal Care (National Institute of
Health publication no. 86–23) were followed.
Laser dissection microscopy
Tubulo-interstitial tissue was dissected using the Leica Microdissection microscope (Leica
Microsystems, Houston, Texas). RNA isolation and quantitative RT-PCR were performed
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essentially according to Asgeirsdottir et al [26]. Experimental details are described elsewhere
[27]. Gene expression was analyzed with a custom made microfluidic card-based low density
array (Applied Biosystems, Nieuwerkerk a/d IJssel, the Netherlands) using the ABI Prism
7900HT Sequence Detection System (Applied Biosystems, Nieuwerkerk a/d IJssel, the Nether-
lands). Composition of the low density array is indicated in Table 1. mRNA expression levels
of CCL21 and 19 were measured separately in a qRT-PCR analysis. Final reaction volume was
10 μl consisting of 3μl cDNA, 5μl SYBR green Supermix (Bio-Rad, Veenendaal, The Nether-
lands), 0,8μl primer mix and 1,2 μl nuclease-free water. Reactions were performed using the
ViiATM 7 Real-Time PCR System (Applied Biosystems, The Netherlands) at 95˚C for 15s,
60˚C for 15s, and 72˚C for 5s, for 40 cycles. Relative mRNA levels were calculated as 2−ΔCT, in
which ΔCT is CTgene of interest−CTβ-actin.
Immunohistochemistry
Four μm acetone fixed frozen kidney sections were blocked for endogenous peroxidase activity
with 0,03% H2O2. Sections were incubated for 1 hr with mouse anti-rat perlecan (10B2, kindly
provided by Dr. Couchman, Biomedicine Institute, University of Copenhagen, Denmark) and
rabbit anti-LYVE-1 (Millipore, Amsterdam, The Netherlands). For stainings LYVE-1 was cho-
sen over podoplanin as lymph vessel marker due to cross-reactivity issues. Binding of primary
antibody was detected by incubating the sections for 30 minutes with rabbit anti-mouse HRP
(DAKO, Belgium) and goat anti-rabbit FITC (SouthernBiotech, USA) diluted in PBS contain-
ing normal rat serum. HRP activity was visualized using the Tetramethylrhodamine System
(PerkinElmer LAS Inc). Nuclei were stained with DAPI. After the staining procedure photo-
micrographs were taken at 640x magnification.
Heparin/heparin derivatives intervention study (Experiment 2)
In this study 38 female DA rats (donors) and 38 male WF rats (recipients) were used. Interven-
tion was done with regular, unfractionated heparin (heparin, m.w. 21,116) and two non-anti-
coagulant heparin derivatives derived from heparin: N-desulfated and N-reacetylated heparin
(N-acetylated heparin, m.w. 18,269) and periodate-oxidized, borohydride-reduced heparin
(glycol split-heparin, m.w. 16,522). Production and characterization of these non-anticoagu-
lant heparin derivatives have been described before [28,29]. The control transplanted group
Table 1. mRNA transcripts quantified in low density and regular qRT-PCR.
Gene name General name Gene symbol Assay ID
Lymphatic markers
Podoplanin Podoplanin Pdpn Rn00571195_m1
Proteoglycans
Perlecan Perlecan LOC313641 Rn01515780_g1
Chemoattractants
Monocyte chemoattractant protein CCL2 Ccl2 Rn00580555_m1
RANTES CCL5 Ccl5 Rn00579590_m1
CX3CL1 CX3CL1 Cx3cl1 Rn00593186_m1
CXCL12 CXCL12 Cxcl12 Rn00573260_m1
CCL19 CCL19 Ccl19 Rn_Ccl19_1_SG
CCL21 CCL21 Ccl21 Rn_Ccl21_1_SG
Reference Gene
Β-actin (2x) Beta-actin Actb Rn00667869_m1
https://doi.org/10.1371/journal.pone.0180206.t001
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received daily vehicle (saline) injections. One day before transplantation, treatment with the
respective formulations was started. The above mentioned groups daily received heparin/
non-anticoagulant heparin derivative between 9.00am and 12.00am dissolved in saline, in-
jected subcutaneously at 2 mg/kg body weigh/day until sacrifice. The treatment dose was cho-
sen according to previous studies [20,21] and is in the physiological range normally used for
the treatment of thrombotic complications. Total follow up was 65±4 days (mean±SD). Ani-
mals were monitored on a daily basis for weight loss, activity and fur condition. When deterio-
rating condition of the animal was suspected, i.e. weight loss of>15% within 1 week and/or
inactivity and/or worsened fur condition, a veterinarian was consulted and if necessary ani-
mals were sacrificed and regarded as drop outs. Upon sacrification animals were put under
anesthesia and the vascular system was flushed with saline. During the follow up of 2–9 weeks,
preterm graft loss occurred in 3 rats in the vehicle-treated group (N = 10), 5 in the unfractio-
nated heparin group (N = 9), 2 in the glycol-split heparin group (N = 9) and 5 in the N-acety-
lated heparin group (N = 10). In total 15 animals dropped out of the experiment, of which 13
were sacrificed and 2 died without prior notice of illness. Graft loss was not significantly differ-
ent among the groups.
Immunohistochemistry
Four μm frozen and formalin-fixed paraffin embedded kidney sections were used for immu-
nohistochemical stainings. Details on fixation, antigen retrieval, antibodies and conjugates
are given in Table 2. All controls (omitting primary and/or secondary antibodies in various
combinations) proved to be negative (not shown). As a lymphatic endothelium marker
VEGFR3, podoplanin and LYVE-1 were tested. VEGFR3 appeared to be the most specific, i.e.
no vessels were VEGFR3+ without being LYVE-1 or podoplanin positive. Hence, where possi-
ble, VEGFR3 was used as a lymphatic endothelial marker. When staining results were signifi-
cantly better or double staining interactions prevented the use of VEGFR3, podoplanin or
LYVE-1 was used as a lymphatic endothelial marker. After the staining procedure 20 photomi-
crographs were taken at 200x magnification from blood vessels or lymph vessels in cortical
regions. Quantification of CD45+ leukocytes adherent to blood vessel endothelium, and leuko-
cytes, MHCII+, ED-1+, CD3+, IDO+, HIS14+, CD103+ and HIS48+ cells inside lymphatic ves-
sels was performed by using Aperio Imagescope software (Leica biosystems, Houston, Texas).
The blood vessel and lymph vessel endothelium was encircled and endothelial circumference
and area of the vessel were calculated. Counted cells were expressed as number of cells per
100 μm of endothelium. Interstitial inflammation was determined by measuring the amount
of CD45+ nucleated cells in the renal cortex using the TissueFAXS software (Tissuegnostics,
Vienna, Austria). Data is expressed as number of nucleated cells positive for CD45 in the
renal cortex. Lymphangiogenesis was determined by staining transplanted and non-trans-
planted kidneys of vehicle treated animals and counting the amount of lymph vessels per high
power field. 10 photomicrographs per animals were randomly taken at 100x magnification
and manually quantified. CCL21 expression in the kidney was determined using 30 photomi-
crographs per animal which were randomly taken at 100X magnification. Quantification was
done using the MacBiophotonics ImageJ program (Rasband, W.S., ImageJ, U.S. National Insti-
tute of Health, Bethesda, Maryland, USA). Data are expressed as % positive stained surface
area.
Quantification of interstitial fibrosis was done by staining sections in the following manner.
Four μm formalin fixed and paraffin embedded sections were deparaffinized and incubated in
Picro Sirius red solution (0,1g Sirius red in 100 ml picric acid) for 1 hour. Thereafter sections
were incubated in 0,01 N HCl for 2 minutes, dehydrated and covered using DEPEX (Klinipath
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BV, Duiven, The Netherlands) mounting medium. Per kidney 25 photomicrographs were ran-
domly taken at 200x magnification and digitally analyzed using MacBiophotonics ImageJ pro-
gram (Rasband, W.S., ImageJ, U.S. National Institute of Health, Bethesda, Maryland, USA).
The amount of interstitial fibrosis was expressed as % positive surface area.
Table 2. Immunohistochemical staining characteristics.







Podoplanin Mouse anti-rat Podoplanin,
(Angiobio, Huissen, Netherlands)
1:100
Goat anti mouse Ig PO (Southern Biotech,
Birmingham, USA); 1:100, 3,3’-
Diaminobenzidine (DAB) (DAKO, Glostrup,





VEGFR3 Goat anti-mouse VEGFR3 (R&D
systems, Minneapolis, USA) 1:40
Rabbit anti- goat Ig HRP (DAKO, Glostrup,
Denmark) 1:100. Tetramethylrhodamine








Rabbit anti-human vWF (Abcam,
Cambridge, UK) 1:400 + Mouse
anti-rat CD45 antibody (clone OX-
1) 1:4
Goat anti-Rabbit Ig-FITC (DAKO, Glostrup,
Denmark) 1:50 + Goat anti-mouse Ig HRP









Goat anti-mouse VEGFR3 (R&D
systems, Minneapolis, USA) 1:40
+ Mouse anti-rat MHCII (Hycult
biotech) 1:100
Rabbit anti-mouse Ig Biotin (DAKO, Glostrup,
Denmark) 1:100 + Rabbit anti- goat Ig HRP
1:100 (DAKO, Glostrup, Denmark).
Strepavidin-FITC 1:25 (DAKO, Glostrup,









Goat anti-mouse VEGFR3 (R&D
systems, Minneapolis, USA) 1:40
+ mouse anti-rat CD68 antibody
(clone ED-1), (abd serotech,
Oxford, UK), 1:500.
Rabbit anti-mouse Ig Biotin (DAKO, Glostrup,
Denmark) 1:100 + Rabbit anti- goat Ig HRP
1:100 (DAKO, Glostrup, Denmark).
Strepavidin-FITC 1:25 (DAKO, Glostrup,








Goat anti-mouse VEGFR3 (R&D
systems, Minneapolis, USA) 1:40
+ Rabbit anti-human CD3; (DAKO,
Glostrup, Denmark) 1:100.
Mouse anti-rabbit IgG HRP (DAKO, Glostrup,










Goat anti-mouse VEGFR3 (R&D
systems, Minneapolis, USA) 1:40
+ Mouse anti-rat HIS48 (Kindly
provided by prof. dr. Hillebrands)
1:2.
Rabbit anti-mouse IgM HRP (Southern
Biotech, Birmingham, USA) 1:100 + Rabbit











Goat anti-mouse VEGFR3 (R&D
systems, Minneapolis, USA) 1:40
+ Rabbit anti-Human IDO
(Millipore, Amsterdam, The
Netherlands) 1:50
Mouse anti-rabbit IgG HRP (DAKO, Glostrup,
Denmark) 1:100 + Donkey anti-Goat IgG









Goat anti-mouse VEGFR3 (R&D
systems, Minneapolis, USA) 1:40
+ Mouse anti-Rat HIS14 (Kindly
provided by prof. dr. Hillebrands)
1:1000. [30]
Donkey anti-Goat IgG (Southern Biotech,
Birmingham, USA) 1:50. + Goat anti-Mouse
IgG1 HRP (Southern Biotech, Birmingham,









Sheep anti-rat Lyve-1 (R&D
systems, Minneapolis, USA) 1:100
+ Mouse anti-rat CD103 (OX-62)
(Hercules, CA, USA) 1:100
Rabbit anti-sheep FITC (Abcam, Cambridge,
UK) 1:50 + Goat anti-mouse IgG1 HRP
(Southern Biotech, Birmingham, USA) 1:100.
Tetramethylrhodamine System (PerkinElmer
LAS Inc)
CCL21 expression Cryosections, Acetone
fixed
CCL21 Goat anti-mouse CCL21 (R&D
systems, Minneapolis, USA) 1:20
Rabbit anti-Goat HRP (DAKO, Glostrup,
Denmark) 1:100, Tetramethylrhodamine
System (PerkinElmer LAS Inc)
https://doi.org/10.1371/journal.pone.0180206.t002
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ELISA competition assay
We used ELISA to evaluate whether heparin/ non-anticoagulant heparin derivatives compete
with the binding of CCL2 and CCL21 to perlecan. For that purpose Maxisorp 96-well flat bot-
tom microtiter plates (U96 from VWR International, Amsterdam, The Netherlands) were
coated overnight in PBS with 5 μg perlecan/ml PBS (Sigma, Zwijndrecht, The Netherlands).
After washing in PBS, wells were blocked with 5% skimmed milk powder in PBS for 1 h. In a
separate microtiter plate, 1,25 μg/ml human recombinant CCL2 or 0,7 μg/ml recombinant
CCL21 (both: PeproTech, Hamburg, Germany) were incubated with a dilution range of either
unfractionated heparin, N-acetylated heparin or glycol-split-heparin for 30 min, then trans-
ferred to the ELISA plate and incubated for 1 h. The concentrations of CCL2 (1.25 μg/ml) an
CCL21 (0,7 μg/ml) were chosen in order to achieve an ELISA signal of around 1.5 OD. The
wells were washed again, and respectively monoclonal mouse anti-human CCL2 IgG1 (1:1000;
eBioscience, Frankfurt, Germany) or Goat anti- mouse CCL21 IgG (1:500, R&D systems, Min-
neapolis, USA) diluted in 1% skimmed milk powder was added for 1 h. After washing, HRP-
labeled goat anti-mouse IgG1, 1:500 (Southern biotech, Birmingham, USA) or Rabbit anti-
Goat Ig, 1:500 (DAKO, Glostrup, Denmark) was added. Substrate reaction was done with
3,3’,5,5’-tetramethylbenzidine substrate (Sigma, Zwijndrecht, The Netherlands) for 15 min in
the dark, and the reaction was stopped by adding 1.5 N H2SO4. Absorbance was measured at
450 nm in a microplate reader. All incubations were done at room temperature in a volume of
100μl/well. All experiments were performed three times in duplicate.
Statistics
mRNA expression levels were analyzed using a one-way ANOVA with Tukey’s post hoc test.
In the rat transplantation experiment, differences between the groups were analyzed using a
Mann Whitney U test adjusted for multiple comparisons. P<0.05 was considered statistically
significant. The inhibitory effect of heparinoids in vitro and lymphangiogenesis were analyzed
by a two-way ANOVA. Spearman correlation analysis was performed to show correlations
between histological parameters and kidney function.
Results
Experiment 1
To show lymphangiogenesis, identify the presence of perlecan in the lymphatic basement
membrane and measure the lymphatic chemokine expression profile in renal transplantation
we counted VEGFR3 positive lymph vessels in non-transplanted donor and allografted kid-
neys and evaluated untreated allograft, isograft and control kidneys for perlecan, podoplanin
and chemokine expression.
Perlecan is a constitute of lymphatic basement membrane and is upregulated in CTD-
associated lymphangiogenesis. Counting the number of VEGFR3+ lymph vessels in non-
transplanted control kidneys and untreated allografted kidneys shows a marked increase in
lymph vessels in allografted kidneys (Fig 1A). Double staining for perlecan and lymph vessels
by LYVE-1 showed perlecan in vascular basement membranes. Partial colocalization of per-
lecan with the LYVE-1 positive lymphatic endothelium reveals perlecan being a constituent
of the lymphatic basement membrane (Fig 1D–1F). qRT-PCR of laser dissected tubulo-in-
terstitium of allografted kidneys showed an increase in both perlecan and podoplanin expres-
sion compared to non-transplanted controls (both p<0,05)(Fig 1B and 1C). The increase of
VEGFR3+ lymph vessels and an increased expression of both perlecan and podoplanin shows
that in transplantation there is an ongoing expansion of the lymphatic system.
Glycol-split heparin increases lymphatic accumulation of APCs
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Tubulo-interstitial chemokine expression is increased in renal transplantation. qRT-
PCR of laser dissected tubulo-interstitium was performed to assess whether newly-formed
lymph vessels were active in producing chemokines. Allograft kidneys show a markedly
increased expression of CCL21 and CCL19 compared to non-transplanted controls (p<0.01,
p<0.001 resp.)(Fig 2A and 2B). Since CCL21 is considered the most important chemokine for
lymphatic migration, these results suggest functionality of the newly formed lymph vessels.
CCL2 and CCL5 are most known for their role in leukocyte influx from the vascular system
into the interstitium. It is however known that they also play a role in leukocyte efflux towards
lymph vessels. In allograft kidneys both CCL2 and CCL5 expression is upregulated in the
tubulo-interstitium compared to non-transplanted controls (p<0.01, p<0.05 resp.)(Fig 2C
and 2D). It is however not known whether the rise in CCL2 and CCL5 expression can be
accounted to either vascular or lymphatic endothelial cells or both. Chemokines CX3CL1 and
CXCL12, which can also be involved in lymphatic leukocyte migration, do not show increased
expression in allografted kidneys (Fig 2E and 2F). These results show that lymphatic endothe-
lium specific chemokines are upregulated in the tubulo-interstitium of renal allografts.
Newly formed lymph vessels in renal transplantation contain predominantly APCs.
Leukocyte accumulation in lymph vessels was scored to determine whether newly formed
lymph vessels are functional. Scoring showed an increase in leukocyte accumulation in lymph
vessel lumen. Intra luminal nucleated cells were seen in approximately 90% of the lymph
vessels scored, giving a strong indication that newly formed lymph vessels were active in
Fig 1. CTD in allografted kidneys is accompanied by lymph vessel formation. (A) Counting of VEGFR3+ lymph vessels revealed a threefold
increase in allografted kidneys compared to the non-transplanted contralateral kidneys from the same donor rats (p<0.01). qRT-PCR of podoplanin and
perlecan in dissected tubulo-interstitium revealed an increase in the expression of the (B) lymphatic endothelial marker podoplanin and (C) the vascular
basement membrane marker perlecan in allografted kidneys (N = 5) compared to non-transplanted control kidneys (N = 5)(both p<0,05). Data are
presented as mean ± SEM. DA-to-DA isografted kidneys (N = 5) did not show an increase in the expression of podoplanin and perlecan. Double
staining for perlecan (D) and lymphatic marker LYVE-1 (E) revealed colocalization of perlecan and lymphatic endothelium (F).
https://doi.org/10.1371/journal.pone.0180206.g001
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accumulating leukocytes (Fig 3A). To investigate which leukocyte subtypes are exiting the
interstitium via the lymphatic route we scored MHCII+ cells (Fig 3B), macrophages (ED-1)
(Fig 3C), dendritic cells (CD103)(Fig 3D), B-cells (HIS14) (Fig 3E), tolerogenic cells (IDO)
(Fig 3F), T-cells (CD3) and neutrophils (HIS48) in the lumen of cortical lymphatic vessels. The
results showed intra-lymphatic cells to be mainly MHCII+, ED-1-, CD103- and HIS14- suggest-
ing antigen-presenting cells are predominantly accumulating in lymph vessels in CTD (Fig
3G). Like ED-1+ macrophages, IDO+ tolerogenic cells and HIS14+ B-cells, T-cells and neutro-
phils are scarce in the lymphatic lumen.
Experiment 2
To evaluate the effect of heparin/ non-anticoagulant heparin derivatives on inflammation,
lymphatic migration and kidney function, transplanted animals were treated daily with the
heparin/ non-anticoagulant heparin derivatives. Inflammation, lymphatic leukocyte accumu-
lation and renal function were determined.
Treatment of renal transplanted rats with glycol split heparin reduced renal leukocyte
recruitment. Glycosaminoglycans have been shown to have anti-inflammatory potential. To
investigate whether heparin/non-anticoagulant heparin derivative treatment could reduce
renal leukocyte recruitment, we scored the number of CD45+ leukocytes adhered to vascular
endothelium, visualized by a van Willebrand factor staining. Adjusted for vascular endothelial
Fig 2. Tubulo-interstitial upregulation of lymphatic chemokines. qRT-PCR for lymphatic chemokines in laser dissected tubulo-interstitium reveals a
strong increase of CCL21, CCL19, CCL2 and CCL5 in allografted kidneys (N = 5) compared to healthy control kidneys (N = 5) (P<0,01, P<0,001,P<0,01 and
P<0,05 respectively). No upregulation was seen in CX3CL1 and CXCL12 expression in allografts. Isografted kidneys (N = 5) showed upregulation of only
CX3CL1. Experiments were done in triplicate. Data are presented as mean ± SEM.
https://doi.org/10.1371/journal.pone.0180206.g002
Glycol-split heparin increases lymphatic accumulation of APCs
PLOS ONE | https://doi.org/10.1371/journal.pone.0180206 June 30, 2017 9 / 21
Fig 3. Intra-lymphatic leukocytes in CTD are mainly HLA-II+, ED-1-, IDO-, CD103- and HIS14- APCs.
Intra-lymphatic leukocytes were scored by counting intra luminal nucleated cells in a podoplanin/PAS double
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length, glycol-split heparin-treated animals showed a significant reduction in the number of
CD45+ leukocytes adherent to the vascular endothelium compared to vehicle-treated animals
(p<0.05)(Fig 4A–4C). No differences were seen between the vehicle treated group and either
the unfractionated heparin or the N-acetylated heparin group. To assess whether the reduction
in endothelial leukocyte adherence in the glycol-split heparin group resulted in a reduction in
the tubulo-interstitial inflammation, CD45+ cells in the interstitium were scored. Values are
expressed as the percentage of CD45+ cells in the renal cortex. In the tubulo-interstitium the
glycol-split heparin group also showed a reduction in leukocyte influx compared to vehicle
treatment (Fig 4D–4F). No differences were seen between the vehicle treated group and either
the unfractionated heparin or the N-acetylated heparin group. Scoring of interstitial leukocyte
subtypes was performed for T-cells (CD3), neutrophils (HIS48), MHC II+ cells, dendritic cells
(CD103) and macrophages (ED-1), however no differences between treatment groups were
found (data not shown).
Treatment of renal transplanted rats with glycol split heparin increased APC accumula-
tion in lymph vessels and worsened renal outcome. To investigate whether glycol-split
heparin treatment and the subsequent reduction of inflammation resulted in a better graft
function we measured plasma creatinine and urea and determined creatinine clearance. Treat-
ment with heparin/ non-anticoagulant heparin derivatives did not alter survival nor resulted
in improved transplant function. Moreover, it seems to worsen kidney function in the glycol-
split heparin treated group. Although not significant, creatinine clearance seems to be lower in
glycol-split treated animals compared to vehicle treated animals (0,4 and 0,6 ml/min resp.)
and plasma urea is higher (43 and 28 mmol/L resp.). Also kidney hypertrophy is the highest in
the glycol-split heparin treated group (Table 3).
To explain why a reduction in inflammation did not lead to a reduced alloresponse and
subsequently to an improved graft function in the glycol-split heparin group, we investigated
the effect of heparin/ non-anticoagulant heparin derivatives treatment on leukocyte efflux
from the interstitium towards the lymphatic system. In a podoplanin/periodic acid—Schiff
double staining the number of leukocytes on the luminal side of the lymphatic endothelium
was scored. Significantly more leukocytes were accumulated on the luminal side of the lym-
phatic endothelium in the glycol-split heparin group compared to the vehicle treated group
(p<0.01) (Fig 5A). Since we showed earlier that the major leukocyte subtype that accumulates
in the lymphatics is MHCII+, we also quantified whether heparin/ non-anticoagulant heparin
derivative treatment could decrease MHCII+ cell accumulation in the lymphatic lumen. The
results showed that accumulation of MHCII+ APCs is borderline increased in glycol-split hep-
arin treated group compared to vehicle treated animals (p = 0,08) (Fig 5B). Heparin and N-
acetylated heparin treated did not show an effect on intra-lymphatic MHCII+ cell accumula-
tion. Staining for dendritic cells (CD103), macrophages (ED-1) and B-cells (HIS14) revealed a
lower mean number of dendritic cells, macrophages and B-cells in the lymphatic lumen com-
pared to MHC II+ APCs in all treatment groups and vehicle treated animals. Moreover, no
effect of treatment was seen in dendritic cell, macrophage and B-cell accumulation in the lym-
phatic lumen (Fig 5C–5E). Also neutrophil (HIS48), tolerogenic cells (IDO) and T-cell (CD3)
staining (A). Intra lymphatic MHCII+ cells (B)(green), macrophages (ED-1)(C)(green),dendritic cells (CD103)
(D)(green), B-cells (HIS14)(E)(red) and tolerogenic cells (IDO)(F)(red) were scored in a double staining with
the lymphatic marker VEGFR3 or Lyve-1. Closed arrows point out intralymphatic accumulation of cells
positive for the respective staining. Open arrows indicate presence of cells positive for the respective staining
outside the lymphatic system. Comparing the intra-lymphatic amount of different leukocyte species in
untreated renal allografts (N = 7) revealed that the main cell accumulating in the tubulo-interstitium is MHCII+,
ED-1-, IDO-, CD103- and HIS14- (G), likely representing antigen presenting cells. Scale bars represent 50μm.
Data are presented as mean ± SEM.
https://doi.org/10.1371/journal.pone.0180206.g003
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accumulation in the lymphatic lumen did not show treatment induced alterations (data not
shown).
Glycol split heparin inhibited binding of CCL21 to immobilized perlecan in vitro and
dispersed CCL21 in vivo. To explain why treatment with glycol-split heparin both leads to
reduced leukocyte influx but increased accumulation in lymph vessels we tested in vitro if hepa-
rin/ non-anticoagulant heparin derivative treatment could inhibit the binding of CCL2 and
Fig 4. Effect of heparin/non-anticoagulant heparin derivative treatment on leukocyte influx in rat renal
transplantation. Adhesion (white arrows) of leukocytes (CD45 in red) to blood vessel endothelium (vWF in green) in kidney
allografts is reduced in the glycol-split heparin treated rats (N = 7) compared to the vehicle treated rats (N = 7) (p<0.05)
(A-C). Moreover, glycol-split heparin treatment (N = 7) also reduces leukocyte count in the interstitium of transplanted rat
kidneys (CD45 in red), compared to vehicle treated animals (N = 7) (p<0.05) (D-F). No significant differences were seen
between heparin (N = 4) or N-acetylated heparin treated animals (N = 5) compared to vehicle treated animals (N = 7). Dotted
lines represent vessel lumen. Scale bars represent 50μm. Data are presented as mean ± SEM.
https://doi.org/10.1371/journal.pone.0180206.g004
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CCL21 to immobilized perlecan. In this experiment we co-incubated CCL2 or CCL21 with
increasing amounts of the heparin/ non-anticoagulant heparin derivatives and measured the
binding of these chemokines to immobilized perlecan. Glycol-split heparin shows the strongest
inhibition of CCL2 binding to perlecan whereas heparin and N-acetylated heparin show equal
ability to inhibit CCL2 binding to perlecan (Fig 6A). Glycol-split heparin and heparin show equal
ability to inhibit the binding of CCL21 to perlecan. Of the non-anticoagulant heparin derivatives,
N-acetylated heparin shows the lowest affinity for CCL21 (Fig 6B), which can be explained by the
lower sulfation degree of N-acetylated heparin compared to heparin and glycol-split heparin.
To test whether treatment with heparin/ non-anticoagulant heparin derivatives had an
effect on the tissue distribution of CCL21, CCL21 was stained and quantified in the renal cor-
tex. In the unmodified heparin and glycol-split heparin group CCL21 positivity was predomi-
nantly seen in vessel like structures, likely lymph vessels (Fig 6D). In contrast, vehicle and N-
acetyl heparin treated animals showed a more expanded staining in the peri-lymphatic intersti-
tium (Fig 6C), besides a lymphatic endothelial staining pattern like in heparin and glycol-split
heparin. Quantification of CCL21 in the renal cortex revealed a reduced CCL21 expression in
the glycol-split heparin group compared to vehicle treated animals (Fig 6E). This might imply
that the strong affinity of heparin and glycol-split heparin for CCL21 causes CCL21 to disperse
from the lymphatic endothelium and its direct periphery, expanding the chemotactic gradient.
Intra-lymphatic leukocytes, rather than interstitial leukocytes or fibrosis correlated
with reduced allograft function. To evaluate potential implications of leukocyte efflux
towards lymph vessels we performed correlation analyses. We correlated serum creatinine,
serum urea and creatinine clearance as renal function parameters with interstitial leukocyte
numbers, interstitial fibrosis and total intra-lymphatic leukocyte numbers. Serum creatinine
levels failed to show a correlation with interstitial inflammation and interstitial fibrosis (r2 =
-0.278 and r2 = 0.126 resp.)(Fig 7A and 7B), but it showed a strong positive correlation with
the total number of intra-lymphatic leukocytes (r2 = 0.443; p = 0,001) (Fig 7C). Serum urea lev-
els also showed a positive correlation with the total number of intra-lymphatic leukocytes
(r2 = 0.483; p<0,001)(Fig 7F), but not with interstitial inflammation and interstitial fibrosis
(r2 = 0.007 and r2 = 0.003 resp.)(Fig 7D and 7E). The same effect can be seen in the correlation
between creatinine clearance and the histological kidney injury parameters. Creatinine clear-
ance showed an inverse correlation with the total number of lymphatic leukocytes (r2 = 0.323;
p = 0,009)(Fig 7I) and no correlation with interstitial inflammation and interstitial fibrosis
(r2 = 0.065 and r2 = 0.009 resp.)(Fig 7G and 7H).
Table 3. Kidney function parameters measured at baseline, 4 and 8 weeks after transplantation. Plasma and urine was collected at baseline, 4 and 8
weeks after transplantation. Both plasma creatinine and urea rose during follow-up after transplantation while the creatinine clearance was reduced in all
groups. Although not significant, glycol-split heparin treatment seemed to result in higher plasma creatinine and urea and lower creatinine clearance compared
to vehicle treated animals. Also kidney hypertrophy, a measure for worsening kidney condition, was highest in glycol-split heparin treated animals.
Timepoint Vehicle (n = 7) Heparin (n = 4) Glycol-split heparin (n = 7) Nac heparin (n = 5)
Δ kidney weight 1,3(0,4–2,3) 1,2(0,9–1,5) 1,5(0,4–3,1) 1,4(1–1,7)
Plasma creatinine (μmol/L) Baseline 19(18–21) 19(19–21) 15(14–17) 15(15–19)
4 weeks after Tx 73(59–120) 64(52–73) 65(54–168) 81(53–84)
8 weeks after Tx 96(73–139) 72(58–99) 136(70–207) 73(58–122)
Creatinine Clearance (ml/min) Baseline 3,0(2,8–3,8) 2,6(2,5–3,0) 3,5(2,7–3,7) 3,0(2,3–3,0)
4 weeks after Tx 0,7(0,4–1,1) 1,0(1,0–1,3) 1,0(0,5–1,2) 0,7(0,1–0,8)
8 weeks after Tx 0,6(0,3–1,0) 0,8(0,5–1,2) 0,4(0,2–0,9) 0,9(0,4–1,0)
Plasma urea (mmol/L) Baseline 6(5–7) 6(5–7) 6(5–6) 6(5–6)
4 weeks after Tx 20(18,3–36) 18(16–20) 20(14–39) 19(15–24)
8 weeks after Tx 28(21–51) 22(18–37) 43(21–64) 27(24–40)
https://doi.org/10.1371/journal.pone.0180206.t003
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Discussion
This study indicates that lymph vessels formed in renal transplants are actively involved in the
migration of leukocytes. These migrating leukocytes consist mostly of MHCII+, CD103-, ED-
1- and HIS14- APCs. We show that treatment of transplanted rats with (non-) anticoagulant
glycol-split heparin increases the presence of leukocytes in lymphatic vessels, predominantly
MHCII+, ED-1-, CD103- and HIS14- APCs, possibly by tissue diffusion of lymphatic chemo-
kines such as CCL21 from lymphatic HSPGs. And finally we show that lymphatic leukocyte
accumulation correlates more with loss of renal function compared to classic histological hall-
marks of alloresponse i.e. interstitial inflammation and fibrosis.
Fig 5. Glycol-split heparin treatment increased intra-lymphatic leukocyte accumulation. Nucleated cells on the luminal side of lymph vessels were
identified and counted to assess the intralymphatic accumulation of leukocytes in heparin/non-anticoagulant heparin derivative treated allograft kidneys.
Glycol-split heparin treatment resulted in an increased lymphatic leukocyte accumulation compared to vehicle treated animals (p<0,01)(A). Data is
expressed as the number of cells per 100 μm of endothelium. Staining for both lymphatic endothelium and MHCII revealed a borderline increase of MHCII
positive cells in the lymphatic lumen in glycol-split heparin treated (N = 7) compared to vehicle treated animals (N = 7) (p = 0,08) (B). Intralymphatic scoring of
CD103+ dendritic cells, HIS14+ B-cells and ED-1+ macrophages did not reveal any effect of heparin/non-anticoagulant heparin derivative treatment on the
intraluminal presence of these cells (C-E). No significant differences were seen between heparin (N = 4) or N-acetylated heparin treated animals (N = 5)
compared to vehicle treated animals (N = 7) in either of the intralymphatic cell populations. Scoring was performed as in Fig 3. Data are presented as
mean ± SEM.
https://doi.org/10.1371/journal.pone.0180206.g005
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Fig 6. Glycol-split heparin revealed a high binding affinity for chemokines resulting in reduced (peri-)lymphatic
CCL21 presence in glycol-split heparin treated kidneys. To determine whether heparin/non-anticoagulant heparin
derivatives are capable of competing with the CCL2 and CCL21 interaction with perlecan, CCL2 or CCL21 were incubated
together with a concentration range of heparin/non-anticoagulant heparin derivatives on a perlecan coated plate. Residual
CCL2 and CCL21 binding to the immobilized perlecan was measured and revealed that glycol-split heparin has the highest
affinity for CCL2 and CCL21 (A+B). Significant differences are expressed as glycol-split heparin compared to heparin (†) and
N-acetylated heparin (*). Experiments were done 3 times in duplicate. In vivo treatment with glycol-split heparin (N = 7)
resulted in a reduced CCL21 staining of (peri-)lymphatic areas compared to vehicle treated animals (N = 7) (C-E). Lymph
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It is an ongoing debate whether newly-formed lymph vessels are actively involved in leuko-
cyte migration towards lymph nodes [5]. Our results indicate that the newly formed lymph
vessels are active in producing chemokines and attracting leukocytes. Furthermore we show
an upregulation of perlecan and podoplanin expression in transplanted kidneys, which might
suggest an increase in the formation of lymph vessels and underlying basement membrane
which hosts perlecan as one of its proteoglycans. Perlecan, amongst other proteoglycans, acts
as a docking platform for lymphatic chemokines like CCL21 and thereby facilitates the forma-
tion of a chemotactic gradient for leukocytes in the lymphatic basement membrane. CCL21 is
seen as the most important chemokine for lymphatic control of migration [18]. In our study
vessels are pointed with white arrows. Scale bars represent 50μm. * = p<0,05, ††/** = p<0,01, †††/*** = p<0,001. Data are
presented as mean ± SEM.
https://doi.org/10.1371/journal.pone.0180206.g006
Fig 7. Kidney function correlated with lymphatic leukocytes. Correlation analysis between kidney function (plasma creatinine, plasma urea and
creatinine clearance) and histological parameters (interstitial inflammation, interstitial fibrosis and lymphatic leukocytes) revealed that there is no correlation
between kidney function and interstitial inflammation or interstitial fibrosis. However, there was a strong correlation between kidney function and the total
number of intra lymphatic leukocytes (C: p = 0.001, F: p<0.001, I: p<0.01).
https://doi.org/10.1371/journal.pone.0180206.g007
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we show a strong CCL21 expression in the tubulo-interstitium of allografted kidneys. This
finding is in accordance with literature showing that activated primary human dermal lym-
phatic endothelial cells secrete and produce CCL21 upon inflammatory stimuli [31]. Interest-
ingly, treatment of allograft kidneys with glycol-split heparin reduces CCL21 staining in the
kidney.
The migration of leukocytes towards the lymph vessels is of major importance in the devel-
opment of an allograft response. In our study we show that lymphatic leukocyte accumulation
inversely correlates with renal function, as opposed to classic histological damage parameters
like interstitial inflammation and fibrosis [3]. To our knowledge this has not been shown
before. The dominant leukocyte subset migrating across lymphatic endothelium in our study
is the MHCII+, CD103-, ED-1- and HIS 14- APC which shows that it is most likely a subset of
DC. Classical non-lymphoid DCs are devided in a CD103+, CD11b- and a CD103-, CD11b+
group [32]. The main function of CD103+, CD11b- DCs is thought to be cytokine production
and cross-presentation [33]. CD103-, CD11b+ DCs are characterized by their strong expres-
sion of MHC class II and this subset of DCs is therefore thought to be important in the induc-
tion of CD4+ T cells [34,35]. In chronic allograft dysfunction it has been demonstrated before
that CD4+ T cells play a pivotal role in the onset of remodeling [36]. Since the intralymphatic
leukocyte population in our study is MHC class II+ while being CD103-, ED-1- and HIS 14-,
these cells probably function as CD4+ T-cell activating APCs and are most likely dendritic
cells of the CD103-, CD11b+ subtype. Studies using anti-CCL21 antibodies have shown that
CCL21 is critical in DC migration [13]. PCR data in our model shows a substantial increase
in CCL21 expression and staining for CCL21 shows substantial release of CCL21 in the inter-
stitium, without differences in the number of lymph vessel in the tissue. This might be an
explanation why MHCII+, CD103- ED-1- and HIS14- APCs are most abundantly leukocyte
migrating in transplantation.
We could not show a positive effect of heparin/ non-anticoagulant heparin derivatives treat-
ment on graft function and outcome, despite others reported this [20,37,38]. Experiments per-
formed by Braun and colleagues showed that LMWH reviparin can improve renal function
and reduce inflammation in experimental renal transplants [20]. We could repeat the reduc-
tion of inflammation by treatment with glycol split heparin, but we failed to show improved
renal function. This can be explained by the differences in study design, since we treated with
high molecular weight heparin/ non-anticoagulant heparin derivatives and used a full HLA
mismatch model compared to the milder Lewis to Fisher model used in the studies of Braun
et. al. The influence of molecular weight of heparin/ non-anticoagulant heparin derivatives can
be the subject of future research. The most prominent difference with former studies is that we
show an increase in leukocyte accumulation in lymph vessels by treatment with glycol-split
heparin. As far as we know this effect of heparin/ non-anticoagulant heparin derivatives has
never been shown before and might well explain the decreased renal function parameters in
the glycol-split heparin treated group.
In vitro we showed an inhibitory effect of glycol-split heparin on the binding of CCL2 and
CCL21 to immobilized HSPG’s. The effect of glycol-split heparin treatment on leukocyte
influx from the vascular system might be explained by ‘elution’ of chemokines such as CCL2
from endothelial proteoglycans, preventing activating and transmigration of rolling leuko-
cytes. This might explain the reduced influx of leukocytes seen in the glycol-split heparin
treated group. The stronger affinity of glycol-split heparin (in comparison with unmodified
heparin) for CCL2 could be explained by the chain flexibility induced by the presence of glycol
split residues that can allow a better interaction with CCL2.
The increased lymphatic accumulation of leukocytes and the higher binding affinity for
CCL21 in vitro in the glycol-split heparin treated group might indicate that CCL21 can
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disperse more in vivo by binding to glycol-split heparin. This could expand the chemotactic
gradient and therefore increase leukocyte migration towards lymph vessels. This is supported
by the finding that CCL21 is less abundantly present in the peri-lymphatic area in glycol-split
heparin treated animals. The migration stimulatory effects of HS or heparin have been shown
before in vitro for other heparin binding cytokines and chemokines like CXCL12 (SDF-1) and
IL-8 [39,40]. Another aiding factor might be that HS chains can oligomerize CCL21 which
might increase the affinity for CCR7 [16]. The oligomerization of CCL21 upon binding with
glycol-split heparin might also stimulate the effectiveness of CCL21 to activate interstitial leu-
kocytes, adding to the effect of glycol-split heparin as a CCL21 potentiator. Lately more evi-
dence is accumulating which indicates that HS might act as a co-receptor for chemokine
presentation [16,41]. In vitro heparin, like glycol-split heparin, also showed a high binding
affinity for CCL21 and subsequently heparin treatment of transplanted kidneys showed a high
dispersion of CCL21 in vivo. Heparin treatment, however, failed to show increased DC accu-
mulation in lymph vessels. This discrepancy might be explained by the fact that glycol splitting
of heparin makes it less vulnerable to heparanase cleaving, an abundant enzyme in inflamma-
tion [42].
The results in our study lead to the conclusion that heparin/ non-anticoagulant heparin
derivative treatment in transplantation is not beneficial for graft function and survival. We do,
however, show a novel effect of heparinoids in inflammation. The increase of leukocyte traf-
ficking towards lymph vessel is certainly not preferable in inflammatory conditions like trans-
plantation. However, in conditions in which increased antigen presentation is desired this
effect can be beneficial. The trafficking and transmigration of DCs has been of interest in mul-
tiple research areas such as vaccine and cancer research [43]. In these research fields it has
been shown that in vivo stimulation can activate DCs and increase their homing [44]. Since we
show this effect for glycol-split heparin, it might be that glycol-split heparin is of interest in
these fields. In transplantation the focus of DC research has mainly been on the in vitro propa-
gation of tolerogenic donor and recipient DCs to induce T lymphocyte allograft tolerance [45].
DC homing is of major importance in these therapies so glycol-split heparin could be a valu-
able addition to these studies as well.
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